Globus Medical FY2025 EPS Forecast Raised by Zacks Research

Globus Medical, Inc. (NYSE:GMED) – Analysts at Zacks Research boosted their FY2025 earnings per share estimates for shares of Globus Medical in a research note issued to investors on Friday, October 24th. Zacks Research analyst Team now forecasts that the medical device company will post earnings per share of $3.21 for the year, up from their prior estimate of $3.20. The consensus estimate for Globus Medical’s current full-year earnings is $3.44 per share. Zacks Research also issued estimates for Globus Medical’s FY2026 earnings at $3.64 EPS, Q1 2027 earnings at $0.89 EPS and Q3 2027 earnings at $1.12 EPS.

A number of other equities analysts have also recently weighed in on the company. Morgan Stanley decreased their price target on Globus Medical from $75.00 to $68.00 and set an “overweight” rating for the company in a report on Tuesday, July 15th. Wall Street Zen cut shares of Globus Medical from a “buy” rating to a “hold” rating in a research report on Friday, September 26th. Royal Bank Of Canada set a $88.00 target price on shares of Globus Medical in a research report on Friday, October 10th. Wells Fargo & Company reduced their target price on shares of Globus Medical from $76.00 to $66.00 and set an “overweight” rating on the stock in a research report on Friday, August 8th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Globus Medical in a research report on Wednesday, October 8th. Seven investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $84.55.

Globus Medical Stock Performance

Shares of NYSE:GMED opened at $62.83 on Monday. Globus Medical has a 1 year low of $51.79 and a 1 year high of $94.93. The stock has a market capitalization of $8.49 billion, a P/E ratio of 24.17, a PEG ratio of 1.73 and a beta of 1.12. The stock has a 50-day simple moving average of $59.39 and a 200-day simple moving average of $60.34.

Globus Medical (NYSE:GMED) last posted its quarterly earnings results on Thursday, August 7th. The medical device company reported $0.86 EPS for the quarter, beating the consensus estimate of $0.76 by $0.10. The company had revenue of $745.34 million during the quarter, compared to analysts’ expectations of $738.91 million. Globus Medical had a return on equity of 10.65% and a net margin of 13.58%.The firm’s revenue was up 18.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.75 EPS.

Institutional Investors Weigh In On Globus Medical

Several large investors have recently added to or reduced their stakes in GMED. Vanguard Group Inc. increased its holdings in shares of Globus Medical by 0.4% during the first quarter. Vanguard Group Inc. now owns 10,909,082 shares of the medical device company’s stock valued at $798,545,000 after purchasing an additional 45,248 shares during the period. Burgundy Asset Management Ltd. increased its holdings in shares of Globus Medical by 24.3% during the second quarter. Burgundy Asset Management Ltd. now owns 3,481,438 shares of the medical device company’s stock valued at $205,474,000 after purchasing an additional 679,691 shares during the period. Sculptor Capital LP increased its holdings in shares of Globus Medical by 31.9% during the second quarter. Sculptor Capital LP now owns 2,760,688 shares of the medical device company’s stock valued at $162,936,000 after purchasing an additional 667,850 shares during the period. William Blair Investment Management LLC increased its holdings in shares of Globus Medical by 5.8% during the second quarter. William Blair Investment Management LLC now owns 2,405,031 shares of the medical device company’s stock valued at $141,945,000 after purchasing an additional 131,244 shares during the period. Finally, Geneva Capital Management LLC increased its holdings in shares of Globus Medical by 13.6% during the second quarter. Geneva Capital Management LLC now owns 2,082,788 shares of the medical device company’s stock valued at $122,926,000 after purchasing an additional 249,141 shares during the period. 95.16% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Ann D. Rhoads sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $58.46, for a total transaction of $584,600.00. Following the sale, the director directly owned 25,384 shares of the company’s stock, valued at approximately $1,483,948.64. This represents a 28.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 18.54% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.